AVADEL PHARMACEUTICALS PLC Reports $60,000 in Lobbying Efforts
Key Lobbying Focus
AVADEL PHARMACEUTICALS PLC recently revealed $60,000 in lobbying expenses for the fourth quarter of 2024. This disclosure, part of a new Lobbying Disclosure Act filing, highlights the company’s focus on various topics, notably the “Prescription Drug Competition Issues” and the Increasing Prescription Drug Competition Act (H.R.4692/S.574).
Insider Trading Insights
In terms of insider trading for AVDL, company insiders have executed seven trades involving $AVDL stock in the past six months. Notably, all trades were purchases, indicating confidence in the company’s future. Here’s a detailed look at these transactions:
- THOMAS S MCHUGH (Chief Financial Officer) completed 2 trades, acquiring 7,300 shares with no sales.
- GEOFFREY MICHAEL GLASS conducted 2 trades, purchasing 20,279 shares without sales.
- GREGORY J DIVIS (Chief Executive Officer) also made 2 trades, buying 10,000 shares and selling none.
- LINDA PALCZUK bought 3,000 shares.
For those interested in tracking insider transactions, visit Quiver Quantitative’s insider trading dashboard.
Recent Hedge Fund Activity
Institutional interest in AVDL has been notable, with 101 investors increasing their shareholdings and 63 reducing theirs in the latest quarter. Here are some highlights of the recent trading activity:
- VIVO CAPITAL, LLC added 2,684,109 shares in Q3 2024, reflecting a significant investment increase.
- GOLDMAN SACHS GROUP INC increased their holdings by 1,859,968 shares in Q3 2024.
- POLAR CAPITAL HOLDINGS PLC decreased its position by 1,726,387 shares (-26.3%) in Q3 2024.
- TRI LOCUM PARTNERS LP snapped up 1,660,955 shares in Q3 2024.
- ADAGE CAPITAL PARTNERS GP, L.L.C. sold 994,738 shares (-100.0%) in Q3 2024.
- MILLENNIUM MANAGEMENT LLC made a substantial addition of 964,257 shares (+7007.2%) in Q3 2024.
- PENN CAPITAL MANAGEMENT COMPANY, LLC purchased 608,399 shares in Q3 2024.
To keep up with hedge funds’ stock portfolios, check out Quiver Quantitative’s institutional holdings dashboard.
This article is not financial advice. For more information, refer to Quiver Quantitative’s disclaimers.
This article was originally published on Quiver News; read the full story.
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
